GE Healthcare Life Sciences has handed over its 1000th ÄKTAprocess to Rentschler Biotechnologie for use in the expanded biopharmaceutical manufacturing capabilities Rentschler has established in Laupheim, Germany.

The equipment supplied by GE features an automated process and manufacturing scale chromatography system. The offshoot of the US conglomerate said its biomanufacturing technologies such as the XDR 2000L bioreactor, the associated seed trains of 50, 200 and 500 L as well as the new ÄKTAprocess, which will be used in the reactor, all play a key role in Rentschler's new single-use manufacturing line.

Peter Rogge, vice president of USP Production at Rentschler, said the new line "will further enhance our ability to deliver high quality projects for companies around the globe," adding that the GE technology is also enabling an increase in Europe of next-generation manufacturing capabilities.